



# A Race against Time: Reduced Azithromycin Susceptibility in *Salmonella enterica* Serovar Typhi in Pakistan

Junaid Iqbal,<sup>a</sup> Irum F. Dehraj,<sup>a</sup> Megan E. Carey,<sup>b</sup> Zoe A. Dyson,<sup>b,c,d</sup> Denise Garrett,<sup>e</sup> Jessica C. Seidman,<sup>e</sup> Furqan Kabir,<sup>a</sup> Senjuti Saha,<sup>f</sup> Stephen Baker,<sup>b</sup>  Farah N. Qamar<sup>a</sup>

<sup>a</sup>Department of Paediatrics and Child Health, Aga Khan University, Karachi, Pakistan

<sup>b</sup>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Department of Medicine, University of Cambridge, Cambridge, United Kingdom

<sup>c</sup>Department of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Victoria, Australia

<sup>d</sup>London School of Hygiene and Tropical Medicine, London, United Kingdom

<sup>e</sup>Sabin Vaccine Institute, Washington, DC, USA

<sup>f</sup>Child Health Research Foundation, Dhaka, Bangladesh

**ABSTRACT** Antimicrobial resistance is an ongoing issue in the treatment of typhoid fever. Resistance to first-line antimicrobials and extensively drug resistant (XDR) *Salmonella* Typhi isolates in Pakistan have left azithromycin as the only remaining effective oral treatment. Here, we report the emergence of organisms with a single point mutation in *acrB* gene, implicated in azithromycin resistance, in a *S. Typhi* isolate from Pakistan. The isolation of this organism is worrisome and highlights the significance of the introduction of typhoid conjugate vaccine in South Asia.

**IMPORTANCE** The emergence of XDR *Salmonella* Typhi in Pakistan has left azithromycin as the only viable oral treatment option. Here, we report the detection of an azithromycin resistance-associated mutation in one *S. Typhi* isolate. This finding is important because any possible spread of azithromycin resistance in *S. Typhi* isolates would make it nearly impossible to treat in outpatient settings due to the need of injectable antibiotics. Our findings also signify the importance of introduction of typhoid conjugate vaccine in regions of endemicity such as Pakistan.

**KEYWORDS** *Salmonella* Typhi, typhoid fever, antimicrobial resistance, azithromycin higher MIC, Pakistan

Typhoid fever, the disease caused by the bacterium *Salmonella* Typhi, is responsible for an estimated 11.8 million infections and 128,200 deaths annually worldwide (1). *S. Typhi* is a human-restricted pathogen that is transmitted via the fecal-oral route. Typhoid mortality ranged from 10–30% of cases in the preantimicrobial era (2), but when treated with effective antimicrobials, typhoid has a case fatality rate of <1% (3). The rise of multidrug resistance (MDR) in the 1990s (4), followed by fluoroquinolone resistance (5), resulted in limited treatment options. The emergence and spread of an extensively drug-resistant (XDR) *S. Typhi* variant in Pakistan (6, 7), which is resistant to chloramphenicol, ampicillin, co-trimoxazole, streptomycin, fluoroquinolones, and third-generation cephalosporins, has left azithromycin as only realistic option for typhoid treatment in Pakistan (8). The recent report of azithromycin-resistant *S. Typhi* in Bangladesh highlights the issues associated with the reliance on this drug and signals the potential of untreatable typhoid (9).

Typhoid is notifiable in Pakistan, and the Aga Khan University has conducted standardized prospective facility and laboratory-based blood culture surveillance in outpatient and inpatient wards at Aga Khan University Hospital and Kharadar General Hospital between September 2016 and September 2019 through the Surveillance for Enteric fever in Asia Project (SEAP). These hospitals serve ~30 million people, including densely populated

**Citation** Iqbal J, Dehraj IF, Carey ME, Dyson ZA, Garrett D, Seidman JC, Kabir F, Saha S, Baker S, Qamar FN. 2020. A race against time: reduced azithromycin susceptibility in *Salmonella enterica* serovar Typhi in Pakistan. *mSphere* 5:e00215-20. <https://doi.org/10.1128/mSphere.00215-20>.

**Editor** Mariana Castanheira, JMI Laboratories

**Copyright** © 2020 Iqbal et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Farah N. Qamar, [farah.qamar@aku.edu](mailto:farah.qamar@aku.edu).

**Received** 28 March 2020

**Accepted** 2 July 2020

**Published** 22 July 2020


informal urban settlements. Subjects presenting to outpatient clinics living in predefined catchment areas with three consecutive days of fever for whom a study clinician recommended a blood culture were enrolled. Inpatients with clinical suspicion of typhoid or with nontraumatic ileal perforation were also enrolled. After blood culture, serologically confirmed *S. Typhi* isolates were subjected to antimicrobial susceptibility testing against azithromycin, ampicillin, co-trimoxazole, chloramphenicol, ciprofloxacin, levofloxacin, ceftriaxone, cefepime, cefixime, and ceftazidime by disk diffusion; resistant organisms (according to CLSI guidelines) were confirmed by Etest (bioMérieux, France) (10).

Between the specified dates, 10,080 patients were enrolled in SEAP in Karachi; 2,104 had a positive blood culture for *S. Typhi*, and 139 had a positive blood culture for *S. Paratyphi A*. Six *S. Typhi* isolates exhibited potential azithromycin resistance by disc diffusion (diameter  $\leq 12$  mm). Upon MIC testing, one failed to revive, four isolates had azithromycin MICs ranging between 1 and 2  $\mu\text{g/ml}$  and one *S. Typhi* isolate had an MIC of 12  $\mu\text{g/ml}$  (CLSI susceptibility breakpoint  $\leq 16$   $\mu\text{g/ml}$ ) (10). This places this isolate at the upper range of the wild-type azithromycin susceptibility distribution, with additional resistance to chloramphenicol, fluoroquinolones, and co-trimoxazole, but it was susceptible to third-generation cephalosporins.

We aimed to investigate the genetic basis of the higher azithromycin MIC and place this organism into phylogenetic context with contemporaneous *S. Typhi* through whole-genome sequencing (WGS). Genomic DNA was extracted and subjected to WGS on a HiSeq2500 (Illumina, San Diego, CA) to generate 125-bp paired-end reads. The resulting sequence data were mapped against the CT18 reference sequence (accession no. [AL513382](https://ncbi.nlm.nih.gov/nucl/AL513382)) using the RedDog mapping pipeline to identify single-nucleotide variants (SNVs) and to confirm the *S. Typhi* genomes were within H58 lineage I (4.3.1.1) (7, 9, 11–19). (<https://github.com/katholt/genotyphi>). After removing repetitive sequences and recombination (20), we generated a final alignment 7,661 chromosomal SNVs for 664 isolates (see Table S1 in the supplemental material). Maximum-likelihood phylogenetic trees were inferred from the chromosomal SNV alignments with RAxML (v8.2.9) (21) and visualized in Microreact (22) (<https://microreact.org/project/8FjPCdisk>) and the ggtree package in R (23). SRST2 (24) was used with ARGannot (25) and PlasmidFinder (26) to identify antimicrobial resistance genes and plasmid replicons, respectively. Mutations in *gyrA*, and *parC*, as well as the R717Q mutation in *acrB*, were detected using GenoTyphi (<https://github.com/katholt/genotyphi>).

This higher azithromycin MIC *S. Typhi* isolate (MIC of 12  $\mu\text{g/ml}$ ), was typed as genotype 4.3.1.1 (H58 lineage I), which is the same sublineage at the XDR clade circulating in Pakistan. The organism additionally had single mutation in *gyrA* (S83F), resulting in reduced fluoroquinolone susceptibility. The apparent mechanism of higher MIC against azithromycin was an R717Q mutation in the gene encoding AcrB, a mutation identical to the recently described azithromycin resistant (MIC of  $\geq 32$   $\mu\text{g/ml}$ ) *S. Typhi* 4.3.1.1 in Bangladesh (9). The identification of this mutation in *S. Typhi* in Pakistan raises the possibilities that this was either a *de novo* mutation in the Pakistan-specific 4.3.1.1 cluster or an organism that was part of larger, internationally disseminating, azithromycin-resistant clone. To determine which was more likely, we used a collection of 663 South Asian 4.3.1.1 (H58 lineage I) sequences to contextualize *S. Typhi* isolate FQ2181 (7, 9, 11–19). The resulting phylogenetic tree demonstrated that this was a spontaneous mutation which emerged in Pakistan, since it was distantly related (relative within H58 lineage I) to the organisms with *acrB* mutations in Bangladesh, and independent of the proximal XDR sublineage (Fig. 1).

Typically, the isolation of a single *S. Typhi* exhibiting resistance to the primary treatment would not be a major cause for concern. However, this isolate demonstrates an additional, independent acquisition of the same mutation that has been observed in Bangladesh (9). Given the reliance of azithromycin for the treatment of typhoid and other bacterial infections and the “fluoroquinolone experience,” we predict that we are likely to see more of these homoplasies arising. It is too early to predict how these particular organisms may spread, and it is encouraging that these mutations have not yet been reported in XDR *S. Typhi*. However, given the nature of these mutations, one could arise in XDR *S. Typhi*, and/or the XDR plasmid may be mobilized into an azithromycin-resistant lineage.



**FIG 1** South Asian H58 lineage I (genotype 4.3.1.1) phylogenetic tree ( $n = 664$  genomes). Branches are colored by source country according to the inset legend and first color bar. The second color bar indicates genomes containing the *acrB*-R717Q mutation. The third color bar indicates mutations in the quinolone resistance determining region (QRDR) of genes *gyrA*, and *parC*. The final color bar indicates MDR and XDR sequences.

Pakistan has initiated a nationwide typhoid conjugate vaccine (TCV) rollout program, which began with a mass vaccination in Sindh province in November 2019 (27). Now, there is a race against time in the prevention of untreatable typhoid fever. With one World Health Organization prequalified manufacturer of TCV supplying vaccine for Gavi-eligible countries and several additional manufacturers in late-stage clinical development (28), there is reason to be optimistic about typhoid control. However, the vaccine is not yet available in all countries of endemicity, and effective treatment is still paramount for typhoid control. Consequently, we need to progress with additional intervention strategies and not overlook that antimicrobials have a substantial impact

on typhoid disease control. In addition, as part of this sustained effort, we need to continue to track phenotypic and genotypic antimicrobial resistance in *S. Typhi* to inform best practices for antimicrobial prescribing and the impact of TCV implementation.

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**TABLE S1**, XLSX file, 0.1 MB.

## REFERENCES

1. GBD Typhoid and Paratyphoid Collaborators. 2019. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Infect Dis* 19:369–381. [https://doi.org/10.1016/S1473-3099\(18\)30685-6](https://doi.org/10.1016/S1473-3099(18)30685-6).
2. Butler T, Knight J, Nath SK, Speelman P, Roy SK, Azad MA. 1985. Typhoid fever complicated by intestinal perforation: a persisting fatal disease requiring surgical management. *Rev Infect Dis* 7:244–256. <https://doi.org/10.1093/clinids/7.2.244>.
3. Crump JA. 2019. Progress in typhoid fever epidemiology. *Clin Infect Dis* 68:S4–S9. <https://doi.org/10.1093/cid/ciy846>.
4. Mirza SH, Beeching NJ, Hart CA. 1996. Multidrug-resistant typhoid: a global problem. *J Med Microbiol* 44:317–319. <https://doi.org/10.1099/00222615-44-5-317>.
5. Britto CD, Wong VK, Dougan G, Pollard AJ. 2018. A systematic review of antimicrobial resistance in *Salmonella enterica* serovar Typhi, the etiological agent of typhoid. *PLoS Negl Trop Dis* 12:e0006779. <https://doi.org/10.1371/journal.pntd.0006779>.
6. Yousafzai MT, Qamar FN, Shakoor S, Saleem K, Lohana H, Karim S, Hotwani A, Qureshi S, Masood N, Rauf M, Khanzada JA, Kazi M, Hasan R. 2019. Ceftriaxone-resistant *Salmonella* Typhi outbreak in Hyderabad City of Sindh, Pakistan: high time for the introduction of typhoid conjugate vaccine. *Clin Infect Dis* 68:S16–S21. <https://doi.org/10.1093/cid/ciy877>.
7. Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, Wong VK, Dallman TJ, Nair S, Baker S, Shaheen G, Qureshi S, Yousafzai MT, Saleem MK, Hasan Z, Dougan G, Hasan R. 2018. Emergence of an extensively drug-resistant *Salmonella enterica* serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. *mBio* 9:e00105-18. <https://doi.org/10.1128/mBio.00105-18>.
8. Levine MM, Simon R. 2018. The gathering storm: is untreatable typhoid fever on the way? *mBio* 9:e00482-18. <https://doi.org/10.1128/mBio.00482-18>.
9. Hooda Y, Sajib MSI, Rahman H, Luby SP, Bondy-Denomy J, Santosham M, Andrews JR, Saha SK, Saha S. 2019. Molecular mechanism of azithromycin resistance among typhoidal *Salmonella* strains in Bangladesh identified through passive pediatric surveillance. *PLoS Negl Trop Dis* 13:e0007868. <https://doi.org/10.1371/journal.pntd.0007868>.
10. CLSI. 2018. Performance standards for antimicrobial susceptibility testing, 28th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Wong VK, Baker S, Connor TR, Pickard D, Page AJ, Dave J, Murphy N, Holliman R, Sefton A, Millar M, Dyson ZA, Dougan G, Holt KE, International Typhoid Consortium. 2016. An extended genotyping framework for *Salmonella enterica* serovar Typhi, the cause of human typhoid. *Nat Commun* 7:12827. <https://doi.org/10.1038/ncomms12827>.
12. Britto CD, Dyson ZA, Duchene S, Carter MJ, Gurung M, Kelly DF, Murdoch DR, Ansari I, Thorson S, Shrestha S, Adhikari N, Dougan G, Holt KE, Pollard AJ. 2018. Laboratory and molecular surveillance of paediatric typhoidal *Salmonella* in Nepal: antimicrobial resistance and implications for vaccine policy. *PLoS Negl Trop Dis* 12:e0006408. <https://doi.org/10.1371/journal.pntd.0006408>.
13. Britto CD, Dyson ZA, Mathias S, Bosco A, Dougan G, Jose S, Nagaraj S, Holt KE, Pollard AJ. 2020. Persistent circulation of a fluoroquinolone-resistant *Salmonella enterica* Typhi clone in the Indian subcontinent. *J Antimicrob Chemother* 75:337–341. <https://doi.org/10.1093/jac/dkz435>.
14. Tanmoy AM, Westeel E, De Bruyne K, Goris J, Rajoharison A, Sajib MSI, van Belkum A, Saha SK, Komurian-Pradel F, Endtz HP. 2018. *Salmonella enterica* serovar Typhi in Bangladesh: exploration of genomic diversity and antimicrobial resistance. *mBio* 9:e02112-18. <https://doi.org/10.1128/mBio.02112-18>.
15. Pham Thanh D, Karkey A, Dongol S, Ho Thi N, Thompson CN, Rabaa MA, Arjyal A, Holt KE, Wong V, Tran Vu Thieu N, Voong Vinh P, Ha Thanh T, Pradhan A, Shrestha SK, Gajurel D, Pickard D, Parry CM, Dougan G, Wolbers M, Dolecek C, Thwaites GE, Basnyat B, Baker S. 2016. A novel ciprofloxacin-resistant subclone of H58 *Salmonella* Typhi is associated with fluoroquinolone treatment failure. *Elife* 5:e14003. <https://doi.org/10.7554/eLife.14003>.
16. Ingle DJ, Nair S, Hartman H, Ashton PM, Dyson ZA, Day M, Freedman J, Chattaway MA, Holt KE, Dallman TJ. 2019. Informal genomic surveillance of regional distribution of *Salmonella* Typhi genotypes and antimicrobial resistance via returning travellers. *PLoS Negl Trop Dis* 13:e0007620. <https://doi.org/10.1371/journal.pntd.0007620>.
17. Rahman SIA, Dyson ZA, Klemm EJ, Khanam F, Holt KE, Chowdhury EK, Dougan G, Qadri F. 2020. Population structure and antimicrobial resistance patterns of *Salmonella* Typhi isolates in urban Dhaka, Bangladesh, from 2004 to 2016. *PLoS Negl Trop Dis* 14:e0008036. <https://doi.org/10.1371/journal.pntd.0008036>.
18. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9:357–359. <https://doi.org/10.1038/nmeth.1923>.
19. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing Study. 2009. The sequence alignment/map format and SAMtools. *Bioinformatics* 25:2078–2079. <https://doi.org/10.1093/bioinformatics/btp352>.
20. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, Parkhill J, Harris SR. 2015. Rapid phylogenetic analysis of large samples of recombinant bacterial whole-genome sequences using Gubbins. *Nucleic Acids Res* 43:e15. <https://doi.org/10.1093/nar/gku1196>.
21. Stamatakis A. 2006. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. *Bioinformatics* 22:2688–2690. <https://doi.org/10.1093/bioinformatics/btl446>.
22. Argimon S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, Glasner C, Feil EJ, Holden MTG, Yeats CA, Grundmann H, Spratt BG, Aanensen DM. 2016. Microreact: visualizing and sharing data for genomic epidemiology and phylogeography. *Microb Genom* 2:e000093. <https://doi.org/10.1099/mgen.0.000093>.
23. Yu G, Smith DK, Zhu H, Guan Y, Lam TT-Y. 2017. ggtree: an R package for visualization and annotation of phylogenetic trees with their covariates and other associated data. *Methods Ecol Evol* 8:28–36. <https://doi.org/10.1111/2041-210X.12628>.
24. Inouye M, Dashnow H, Raven LA, Schultz MB, Pope BJ, Tomita T, Zobel J, Holt KE. 2014. SRST2: rapid genomic surveillance for public health and hospital microbiology labs. *Genome Med* 6:90. <https://doi.org/10.1186/s13073-014-0090-6>.
25. Gupta SK, Padmanabhan BR, Diene SM, Lopez-Rojas R, Kempf M, Landraud L, Rolain JM. 2014. ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. *Antimicrob Agents Chemother* 58:212–220. <https://doi.org/10.1128/AAC.01310-13>.
26. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. *In silico* detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895–3903. <https://doi.org/10.1128/AAC.02412-14>.
27. EMRO/WHO. 2019. Pakistan becomes first country to introduce new typhoid vaccine into routine immunization program, p 10–12. World Health Organization, Geneva, Switzerland.
28. Sahastrabudde S, Saluja T. 2019. Overview of the typhoid conjugate vaccine pipeline: current status and future plans. *Clin Infect Dis* 68:S22–S26. <https://doi.org/10.1093/cid/ciy884>.